WO2015056982A1 - Procédé d'induction de cellules souches pluripotentes et cellules souches pluripotentes préparées au moyen dudit procédé - Google Patents
Procédé d'induction de cellules souches pluripotentes et cellules souches pluripotentes préparées au moyen dudit procédé Download PDFInfo
- Publication number
- WO2015056982A1 WO2015056982A1 PCT/KR2014/009702 KR2014009702W WO2015056982A1 WO 2015056982 A1 WO2015056982 A1 WO 2015056982A1 KR 2014009702 W KR2014009702 W KR 2014009702W WO 2015056982 A1 WO2015056982 A1 WO 2015056982A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- extract
- stem cells
- composition
- plant
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 89
- 210000001778 pluripotent stem cell Anatomy 0.000 title abstract description 71
- 230000001939 inductive effect Effects 0.000 title abstract description 17
- 210000004027 cell Anatomy 0.000 claims abstract description 190
- 239000000284 extract Substances 0.000 claims abstract description 185
- 210000000130 stem cell Anatomy 0.000 claims abstract description 142
- 239000000203 mixture Substances 0.000 claims abstract description 137
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 claims abstract description 129
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 claims abstract description 128
- 241000196324 Embryophyta Species 0.000 claims abstract description 107
- 206010020649 Hyperkeratosis Diseases 0.000 claims abstract description 75
- 239000000419 plant extract Substances 0.000 claims abstract description 41
- 241001116459 Sequoia Species 0.000 claims description 73
- 239000002253 acid Substances 0.000 claims description 28
- 238000012258 culturing Methods 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 210000004927 skin cell Anatomy 0.000 claims description 16
- 230000001737 promoting effect Effects 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 13
- 241000558610 Illicium anisatum Species 0.000 claims description 10
- 241000422846 Sequoiadendron giganteum Species 0.000 claims description 9
- 230000003712 anti-aging effect Effects 0.000 claims description 9
- 210000000170 cell membrane Anatomy 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 241000720991 Illicium Species 0.000 claims description 7
- 235000021307 Triticum Nutrition 0.000 claims description 7
- 241000208340 Araliaceae Species 0.000 claims description 6
- 238000002659 cell therapy Methods 0.000 claims description 6
- 210000003491 skin Anatomy 0.000 claims description 6
- 241000546188 Hypericum Species 0.000 claims description 5
- 241000218594 Picea pungens Species 0.000 claims description 5
- 241000209140 Triticum Species 0.000 claims description 5
- 240000006927 Foeniculum vulgare Species 0.000 claims description 4
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 4
- 244000194101 Ginkgo biloba Species 0.000 claims description 4
- 240000000691 Houttuynia cordata Species 0.000 claims description 4
- 235000013719 Houttuynia cordata Nutrition 0.000 claims description 4
- 244000104275 Phoenix dactylifera Species 0.000 claims description 4
- 235000010659 Phoenix dactylifera Nutrition 0.000 claims description 4
- 244000098338 Triticum aestivum Species 0.000 claims description 4
- 244000141009 Hypericum perforatum Species 0.000 claims description 3
- 241001633663 Iris pseudacorus Species 0.000 claims description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 3
- 235000011613 Pinus brutia Nutrition 0.000 claims description 3
- 241000018646 Pinus brutia Species 0.000 claims description 3
- 235000014443 Pyrus communis Nutrition 0.000 claims description 3
- 240000001987 Pyrus communis Species 0.000 claims description 3
- 244000191704 Sida acuta Species 0.000 claims description 3
- 240000004460 Tanacetum coccineum Species 0.000 claims description 3
- ROVGZAWFACYCSP-MQBLHHJJSA-N [2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OC1C(C)=C(C\C=C/C=C)C(=O)C1 ROVGZAWFACYCSP-MQBLHHJJSA-N 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229940015367 pyrethrum Drugs 0.000 claims description 3
- 108010075210 streptolysin O Proteins 0.000 claims description 3
- 241000905358 Actaea pachypoda Species 0.000 claims description 2
- 235000006074 Agastache urticifolia Nutrition 0.000 claims description 2
- 244000111997 Agastache urticifolia Species 0.000 claims description 2
- 241000759271 Alangium Species 0.000 claims description 2
- JSUVCAQGWVUMPD-QXUQJYLISA-N Arjuna Natural products O([C@H]([C@@H](O)C=O)[C@H]1[C@H](O)COC(=O)c2c(c(O)c(O)c(O)c2)-c2c(O)c(O)c3OC(=O)c4c(c(O)c(O)c5OC(=O)c2c3-c45)-c2c(O)c(O)c(O)cc2C(=O)O1)C(=O)c1cc(O)c(O)c(O)c1 JSUVCAQGWVUMPD-QXUQJYLISA-N 0.000 claims description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 2
- 244000020518 Carthamus tinctorius Species 0.000 claims description 2
- 240000006739 Celastrus paniculatus Species 0.000 claims description 2
- 244000028508 Cistus creticus Species 0.000 claims description 2
- 235000013306 Cistus creticus Nutrition 0.000 claims description 2
- 235000000350 Cistus incanus Nutrition 0.000 claims description 2
- 241000233838 Commelina Species 0.000 claims description 2
- 241000931690 Dipsacus laciniatus Species 0.000 claims description 2
- 241000988055 Dipsacus pilosus Species 0.000 claims description 2
- 241000006121 Eucalyptus regnans Species 0.000 claims description 2
- 244000158425 Eucalyptus x virgata Species 0.000 claims description 2
- 235000003460 Eucalyptus x virgata Nutrition 0.000 claims description 2
- 241001572175 Gaza Species 0.000 claims description 2
- 235000011201 Ginkgo Nutrition 0.000 claims description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 2
- 241000972696 Glycosmis Species 0.000 claims description 2
- 241000208251 Gymnema Species 0.000 claims description 2
- 235000003230 Helianthus tuberosus Nutrition 0.000 claims description 2
- 240000008892 Helianthus tuberosus Species 0.000 claims description 2
- 235000015376 Hemidesmus indicus Nutrition 0.000 claims description 2
- 244000187653 Hemidesmus indicus Species 0.000 claims description 2
- 241000122441 Hypericum dolabriforme Species 0.000 claims description 2
- 241000198061 Illicium henryi Species 0.000 claims description 2
- 235000008227 Illicium verum Nutrition 0.000 claims description 2
- 240000007232 Illicium verum Species 0.000 claims description 2
- 235000002598 Inula helenium Nutrition 0.000 claims description 2
- 244000116484 Inula helenium Species 0.000 claims description 2
- 244000134336 Malus baccata Species 0.000 claims description 2
- 235000005079 Malus baccata Nutrition 0.000 claims description 2
- 241000383833 Pachyphyllum Species 0.000 claims description 2
- 235000005205 Pinus Nutrition 0.000 claims description 2
- 241000218602 Pinus <genus> Species 0.000 claims description 2
- 235000008585 Pinus thunbergii Nutrition 0.000 claims description 2
- 241000218686 Pinus thunbergii Species 0.000 claims description 2
- 235000004768 Pistacia lentiscus Nutrition 0.000 claims description 2
- 240000005428 Pistacia lentiscus Species 0.000 claims description 2
- 229920000175 Pistacia lentiscus Polymers 0.000 claims description 2
- 235000015034 Ribes aureum Nutrition 0.000 claims description 2
- 240000004594 Ribes aureum Species 0.000 claims description 2
- 235000002953 Saxifraga stolonifera Nutrition 0.000 claims description 2
- 244000288377 Saxifraga stolonifera Species 0.000 claims description 2
- 241001442052 Symphytum Species 0.000 claims description 2
- 235000005865 Symphytum officinale Nutrition 0.000 claims description 2
- 240000002299 Symphytum officinale Species 0.000 claims description 2
- 235000009330 Terminalia Nutrition 0.000 claims description 2
- 241001534869 Terminalia Species 0.000 claims description 2
- 235000000538 Terminalia arjuna Nutrition 0.000 claims description 2
- 244000071109 Terminalia arjuna Species 0.000 claims description 2
- 241000001522 Terminalia chebula Species 0.000 claims description 2
- 235000011517 Terminalia chebula Nutrition 0.000 claims description 2
- 241000218638 Thuja plicata Species 0.000 claims description 2
- 241000898364 Triadenum walteri Species 0.000 claims description 2
- 241001250587 Veratrum viride Species 0.000 claims description 2
- 235000015277 pork Nutrition 0.000 claims description 2
- 235000012040 Dahlia pinnata Nutrition 0.000 claims 2
- 244000115658 Dahlia pinnata Species 0.000 claims 2
- 235000008512 Magnolia grandiflora Nutrition 0.000 claims 2
- 240000003293 Magnolia grandiflora Species 0.000 claims 2
- 235000004507 Abies alba Nutrition 0.000 claims 1
- 235000003717 Boswellia sacra Nutrition 0.000 claims 1
- 235000012035 Boswellia serrata Nutrition 0.000 claims 1
- 240000007551 Boswellia serrata Species 0.000 claims 1
- 240000004160 Capsicum annuum Species 0.000 claims 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims 1
- 235000007862 Capsicum baccatum Nutrition 0.000 claims 1
- 244000192528 Chrysanthemum parthenium Species 0.000 claims 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims 1
- 241000555925 Elodea nuttallii Species 0.000 claims 1
- 239000004863 Frankincense Substances 0.000 claims 1
- 235000002357 Ribes grossularia Nutrition 0.000 claims 1
- 244000171263 Ribes grossularia Species 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 239000001728 capsicum frutescens Substances 0.000 claims 1
- 235000008384 feverfew Nutrition 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 229930195215 pungen Natural products 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 239000011435 rock Substances 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 abstract description 26
- 239000003814 drug Substances 0.000 abstract description 7
- 230000008672 reprogramming Effects 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 102000002322 Egg Proteins Human genes 0.000 abstract 1
- 108010000912 Egg Proteins Proteins 0.000 abstract 1
- 210000004681 ovum Anatomy 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 27
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 27
- 230000000694 effects Effects 0.000 description 23
- 238000009472 formulation Methods 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 23
- 239000013642 negative control Substances 0.000 description 18
- 210000002950 fibroblast Anatomy 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- 238000010586 diagram Methods 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 14
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 238000013329 compounding Methods 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000036560 skin regeneration Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 10
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 10
- 239000006071 cream Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 101150086694 SLC22A3 gene Proteins 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- 101150033839 4 gene Proteins 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000006143 cell culture medium Substances 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 7
- 230000020411 cell activation Effects 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 7
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 239000007901 soft capsule Substances 0.000 description 6
- 210000001082 somatic cell Anatomy 0.000 description 6
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 5
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 5
- 210000004504 adult stem cell Anatomy 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 235000004883 caffeic acid Nutrition 0.000 description 5
- 229940074360 caffeic acid Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 5
- 238000004040 coloring Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 5
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 5
- 235000001785 ferulic acid Nutrition 0.000 description 5
- 229940114124 ferulic acid Drugs 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 241001138418 Sequoia sempervirens Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920002498 Beta-glucan Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000218666 Metasequoia Species 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000003981 ectoderm Anatomy 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000010374 somatic cell nuclear transfer Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000218645 Cedrus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000218378 Magnolia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 240000000020 Picea glauca Species 0.000 description 2
- 235000008127 Picea glauca Nutrition 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000011481 absorbance measurement Methods 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000032459 dedifferentiation Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- -1 pack Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 235000003499 redwood Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000009168 stem cell therapy Methods 0.000 description 2
- 238000009580 stem-cell therapy Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 210000002444 unipotent stem cell Anatomy 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000003092 Artemisia dracunculus Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241001585562 Callitris columellaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000606540 Chione venosa Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 244000033273 Dahlia variabilis Species 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 235000014486 Hydrangea macrophylla Nutrition 0.000 description 1
- 244000267823 Hydrangea macrophylla Species 0.000 description 1
- 235000008226 Illicium floridanum Nutrition 0.000 description 1
- 240000003157 Illicium floridanum Species 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241001495454 Parthenium Species 0.000 description 1
- AVFIYMSJDDGDBQ-UHFFFAOYSA-N Parthenium Chemical compound C1C=C(CCC(C)=O)C(C)CC2OC(=O)C(=C)C21 AVFIYMSJDDGDBQ-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 235000008124 Picea excelsa Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001647091 Saxifraga granulata Species 0.000 description 1
- 241000422847 Sequoiadendron Species 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000002520 cambial effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 235000019987 cider Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000000442 meristematic effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 125000001757 shikimic acid group Chemical group 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0204—Specific forms not provided for by any of groups A61K8/0208 - A61K8/14
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
- A61K8/022—Powders; Compacted Powders
- A61K8/0225—Granulated powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9761—Cupressaceae [Cypress family], e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9767—Pinaceae [Pine family], e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/76—Undefined extracts from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Definitions
- the present specification relates to a method for inducing pluripotent stem cells by reprogramming and / or dedifferentiating adult differentiated cells, to pluripotent stem cells prepared by the method and to a composition comprising the pluripotent stem cells.
- the present disclosure also relates to a pharmaceutical composition or cosmetic composition comprising pluripotent stem cells.
- the present invention also relates to a composition for stem cell activation, skin cell proliferation, skin regeneration or anti-aging.
- Stem cells are cells capable of differentiating into the various cells constituting biological tissues, which collectively refer to the undifferentiated cells obtained before the differentiation obtained in each tissue of the embryo, fetus and adult.
- pluripotent stem cells refer to stem cells having versatility capable of differentiating into all three germ layers of endoderm, mesoderm, and ectoderm.
- stem cells In classifying stem cells, depending on the anatomical location, the function of the cell, the type of antigen expressed on the cell surface, the transcription factors, the proteins produced by the cell, and the stem cells They can be sorted according to the specific cell types they can produce.
- the most commonly used and relatively clear classification of these various classifications depends on the individual from which the stem cells were isolated. When separated from the embryo (embryo) it can be divided into embryonic stem cells (ESry cells) and adult stem cells (adult stem cells) when separated from the adult.
- embryonic stem cells embryonic stem cells
- adult stem cells adult stem cells
- ES cells embryonic stem Embryonic stem cells
- adult stem cells adult stem cells
- Embryonic stem cells formed from this inner cell mass are one individual. It can be said to be a pluripotent stem cell that has the potential to differentiate into the cells of all the tissues that make up. In other words, embryonic stem cells are undifferentiated cells capable of unlimited proliferation, can differentiate into all cells, and unlike adult stem cells, can make germ cells and can be inherited for the next generation.
- Embryonic stem cells such pluripotent stem cells
- Embryonic stem cells have serious religious and ethical problems of embryo destruction in the cell manufacturing process, and because of their lack of immunocompatibility between individuals due to limited embryos, transplant rejection reactions when developed as cell therapeutics can not avoid.
- various methods have been attempted to artificially prepare cells with pluripotent cells such as embryonic stem cells or embryonic stem cells using adult-derived cells.
- Representative methods include somatic cell nuclear transfer (SCNT), cell fusion with ES cell, and reprogramming by defined factor.
- SCNT somatic cell nuclear transfer
- the somatic cell nuclear transfer method has a big limitation in that its efficiency is very low and a large number of eggs are needed which can contain ethical problems.
- the cell fusion method has a big problem in terms of cell stability because the induced cells have two more pairs of genes.
- the most recently introduced technology, the specific factor injection method uses a virus containing a carcinogen and has a serious problem of cancer cell formation.
- the present inventors have obtained dedifferentiated stem cells as extracts of induced pluripotent stem cells (iPS) derived from animals, but there are some limitations.
- iPS induced pluripotent stem cells
- One aspect of the present invention is to solve the problems of the prior art as described above, to propose a method for producing a pluripotent stem cells with no ethical problems and secured stability, safety.
- the present invention proposes a method of inducing human-derived dedifferentiated stem cells that were difficult to realize in the prior art.
- the present inventors have developed a method that can induce pluripotent stem cells having the same genetic background as the adult from which the cells are separated using adult-derived cells, and thus from adult-derived cells having various genetic backgrounds. By deriving the same result, it is suggested that the method of the present invention is a suitable invention capable of producing pluripotent stem cells.
- an aspect of the present invention provides a method for inducing stem cells by treatment of adult extracts, plant extracts, plant stem cell extracts or compositions containing them, such as shikimic acid, shikimic acid do.
- one aspect of the present invention comprises the steps of extracting an extract comprising the active ingredient in plant stem cells or all kinds of induced pluripotent plant stem cells induced by various methods; Injecting the extract into adult-derived cells; And it provides a method for producing a custom pluripotent stem cells comprising the step of producing a pluripotent cells, such as embryonic stem cells through the culture of the cells injected with the extract.
- an aspect of the present invention comprises the steps of injecting Shikimic acid, plant extracts containing Shikimic acid, plant stem cell extract or composition comprising them into adult-derived cells; And it provides a method for producing a stem cell further comprising the step of culturing cells injected with shikimic acid, extract or composition.
- the extract may be a callus extract.
- the method may further comprise the step of treating the cell membrane permeation promoting compound for the adult cells before the injection of the extract.
- the cell membrane permeation promoting compound may include streptolysin O and digitonin, but is not limited thereto, as long as it facilitates the injection of the shikimic acid or extract according to the present invention into the cell membrane.
- the method may further comprise the step of culturing the adult-derived cells injected with the extract to the support cell layer to further culture.
- the support cell may include, but is not limited to, STO cells.
- an aspect of the present invention comprises the steps of extracting an extract containing the active ingredient in plant stem cells, callus or all kinds of induced pluripotent plant stem cells induced by various methods; Injecting the extract into adult-derived cells; The extract-injected cells are cultured in a general cell culture solution and transferred to a culture condition with a feeder cell layer, and further comprising culturing in embryonic stem cell culture, to provide a customized pluripotent stem cell production method.
- one aspect of the present invention provides a stem cell produced by the method.
- one aspect of the present invention provides a composition comprising a stem cell.
- the present invention by using Shikimic acid, plant extracts or plant stem cell extracts containing the same, reprogramming and / or dedifferentiating the differentiated cells of the adult inducible Pluripotent stem cell (inducible Pluripotent stem cell) : iPSC), a method for inducing a pluripotent stem cell prepared by the method and a cell therapy comprising the pluripotent stem cells.
- the plant extract or plant stem cell extract containing shikimic acid used in the present invention is Sequoiadendron giganteum , yellow iris ( Iris pseudoacorus ), fat pork (pork potato) ( Helianthus tuberosus ), silver blue spruce (blue spruce) ) ( Picea pitchs ), Glauka spruce (white spruce) ( Picea glauca ), Eucalyptus ( Eucalyptus sieberiana ), Eucalyptus regnans , Western cypress ( Thuja plicata ), Date palm (Red Ceda, Phoenix dactylifera ), dahlia Dahlia variabilis , luminous tree ( Malus baccata ), Pear ( Pyrus communis ), wheat ( Triticum ), pine ( Pinus densifloraa ), gom ( Pinus thunbergii ), Isolum ( Ilicium anisatum ), Magnolia
- the present invention also relates to a composition for stem cell activation, skin regeneration, or anti-aging or a pharmaceutical or cosmetic composition comprising the stem cells prepared by the above method.
- the best method of producing stem cells, plant stem cells or plants including extracts of all kinds of induced Pluripotent Plant Stem cells derived from various methods, shikimic acid, shikimic acid Extracts or compositions comprising them can be used, and this method will also be a wide variety of fabrication methods that can be applied to all cells of all species, including humans of various genetic backgrounds.
- the method of the present invention by using a plant-derived stem cell extract, it is possible to manufacture a custom pluripotent stem cells with no ethical problems and secured safety.
- FIG. 1 is a schematic diagram showing the entire experimental process of inducing pluripotent stem cells according to the method of the present invention.
- Figure 2 is a diagram showing induced pluripotent stem cells observed on day 5 after treatment with plant stem cell extract.
- FIG. 3 is a diagram showing induced pluripotent stem cells observed on day 8 of treatment with plant stem cell extracts and on day 2 of transfer to feeder cells.
- FIG. 4A is a diagram showing induced pluripotent stem cells observed after 4 passages after transfer to feeder cells at 32 days of treatment with plant stem cell extracts. 4B shows a typical embryonic stem cell.
- FIG. 5 is a diagram showing the alkaline phosphatase staining results of induced pluripotent stem cells observed after four passages after transfer to feeder cells after treatment with plant stem cell extracts.
- FIG. 6A is a diagram showing induced pluripotent stem cells observed after 7 passages after transfer to feeder cells at 50 days of treatment with plant stem cell extracts and alkaline phosphatase staining of the cells. The figure shows the result.
- FIG. 6B is a diagram showing the results of staining of human pluripotent stem cells and alkaline phosphatase induced by 4 factor virus of Yamanaka.
- Figure 7 is a diagram showing the gene expression of pluripotent stem cells induced by the method of the present invention.
- Shikimic acid represents Shikimic acid having a structure of the present formula [Formula 1].
- Figure 9 is a schematic diagram showing the entire experimental process of inducing pluripotent stem cells using the plant stem cell extract containing Shikimic acid or the same according to the method of the present invention.
- FIG. 10 is a diagram showing the expression of Oct3 / 4 gene in HDF after treatment with shikimic acid or sequoia callus extract.
- Figure 11 shows the expression of Oct3 / 4 gene in HDF after treatment with sikimic acid at different concentrations.
- FIG. 12 is a diagram showing the increase in the expression of ALP after treatment with shikimic acid or sequoia callus extract.
- Figure 13 is a diagram showing the increase in the expression of ALP after treatment with sikimic acid by concentration.
- FIG. 14 is a diagram showing the colony generating ability of the dermal cells after treatment with shikimic acid or sequoia callus extract.
- 15 is a graph showing colony production of dermal cells after treatment with shikimic acid or sequoia callus extract.
- 16 is a diagram showing the colony generating ability of the dermal cells after treatment with shikimic acid by concentration.
- Figure 17 is a graph showing the colony generating capacity of dermal cells after treatment with shikimic acid by concentration.
- 18 is a graph showing the increase in the proliferative capacity of dermal cells after treatment with shikimic acid or sequoia callus extract.
- Korean Patent Application No. 10-2013-0123860 filed October 17, 2013, is incorporated herein by reference in its entirety for all purposes. This application also claims the benefit of Korean Patent Application No. 10-2013-0123860, which is hereby incorporated by reference in its entirety.
- c) providing a method of inducing a customized pluripotent stem cell comprising the step of culturing the cells injected with the extract, and producing a pluripotent cell such as an embryonic stem cell.
- one aspect of the present invention is Shikimic acid; Plant extracts comprising shikimic acid; Plant stem cell extract comprising shikimic acid; Or it provides a method for producing a stem cell comprising treating the composition containing them to adult derived cells.
- an aspect of the present invention comprises the steps of injecting Shikimic acid, plant extracts containing Shikimic acid, plant stem cell extracts containing Shikimic acid or a composition containing them to adult-derived cells; And it provides a method for producing a stem cell further comprising the step of culturing cells injected with shikimic acid, extract or composition.
- the extract herein may be a callus extract.
- the plant extract or plant stem cell extract may comprise shikimic acid, caffeic acid or ferulic acid.
- “Simkimic acid” as used herein may have the following general formula (1), and means the broadest concept including precursors, derivatives, and the like thereof.
- the molecular weight of the shikimic acid may also be 174.15 g / mol.
- caffeic acid may have the following Chemical Formula 2, and means the broadest concept including a precursor derivative thereof, and the like, and may have a molecular weight of 180.16 g / mol. Caffeic acid also means phenolic compounds contained in fruits such as pears, including coffee beans, and medicinal plants such as basil, thyme, bananas, tarragon, oregano, and dandelion.
- ferulic acid may have the following Chemical Formula 3, and means the broadest concept including a precursor derivative thereof, and the like, and may have a molecular weight of 191.18 g / mol. Ferulic acid is also a precursor to lignin, which forms the cell walls of plants, and is abundantly contained in plant cell walls and is found in plant seeds such as wheat, oats, coffee, apples, oranges, and peanuts.
- 'stem cells' refers to master cells that can be regenerated without limitation to form specialized cells of tissues and organs.
- Stem cells are developable pluripotent or pluripotent cells. Stem cells can divide into two daughter cells, or one daughter cell and one derived ('transit') cell, and then proliferate into mature, fully formed cells of the tissue.
- the term 'embryonic stem cell' refers to a cell having pluripotency as a cell cultured after separation from an inner cell mass (blast cell) of blastocyt, which is an early development after fertilization. Refers to.
- iPS induced pluripotent stem cells or induced pluripotent stem cells (iPS) extract' refers to pluripotent stem cells or induced pluripotent stem cells induced or cultured in various ways in vitro
- Induced Pluripotent Stem cells (iPS) refers to a material that is separated by a method such as centrifugation after crushing finely by a physical-chemical method.
- plant stem cell is a cambium-derived plant stem cell.
- it includes pure plant stem cells (CMC Cambial Meristematic Cell) in the physically intact state in the formation layer sandwiched between the water and phloem of the plant.
- plant stem cells is the broadest concept as including all kinds of induced pluripotent plant stem cells derived by various methods.
- callus (callus, or callus, wound tissue, or oily tissue) is an undifferentiated irregular cell mass that is representative of tumor tissue formed by meristems formed around the wound when the plant is injured. to be. Plants are composed of meristems that divide into cells and permanent tissues that do not. Cells are formed when the cells of the meristem are first placed in the nutrient medium and grown. Thereafter, an embryonic embryo is formed and differentiated into plants. This callus is also commonly called “plant stem cells.” There is no restriction
- pluripotent stem cell' is a multifunctional (pluripotent) that can be differentiated into all three germ layers constituting the living body (endoderm), mesoderm (mesoderm), ectoderm (ectoderm) Refers to stem cells). Embryonic stem cells are traditionally called stem cells in this category.
- custom pluripotent stem cells' used in the present invention refers to the genetically identical donor cells and induced pluripotent stem cells used to make pluripotent stem cells, which are derived from a custom pluripotent stem cell originated from a donor cell. Indicate that it is a cell
- 'custom pluripotent stem cells', 'dedifferentiated stem cells', 'induced pluripotent stem cells' may be used interchangeably.
- the term 'adult-derived cell' refers to a cell derived from an adult that is born and alive as opposed to an embryonic cell.
- the term "differentiation” refers to a phenomenon in which structures or functions are specialized while cells divide and proliferate and grow, that is, a cell or tissue of an organism has a shape or function to perform a task given to each. It means to change.
- a relatively simple system is divided into two or more qualitatively different sub systems. For example, qualitatively between parts of a living organism that were almost homogeneous in the first place, such as head or torso distinctions between eggs that were initially homogenous in the development, or cells such as muscle cells or neurons.
- Phosphorus difference or as a result, is a state divided into subclasses or subclasses that can be distinguished qualitatively.
- the plant may be a sequoia.
- the plant stem cells may be callus (callus).
- the plant stem cells may be sequoia stem cells.
- the plant stem cell extract may be a callus extract.
- the extract may be Sequoia callus extract.
- the sequoia may be a sequoiadendron giganteum .
- the extract or composition may comprise shikimic acid.
- the composition may comprise a concentration of 10-MuM to 30 mM simkimic acid based on the total volume of the composition.
- the composition is based on the total volume of the composition of the shikimic acid, plant extract or plant stem cell extract 10uM or more, 20uM or more, 30uM or more, 50uM or more, 100uM or more, 1mM or more, 5mM or more It may include 10mM or more, 20mM, or 30mM or more, and may include 1M or less or 100M or less.
- the shikimic acid included in the composition may be included at a concentration of at least 0.1 mM, at least 0.5 mM, at least 0.6 mM, at least 0.7 mM, at least 0.8 mM or at least 0.9 mM based on the total volume of the composition or at most 5 mM, at most 4 mM, at most 3 mM, 2 mM Or less, 1.5 mM or less, 1.4 mM or less, 1.3 mM or less, 1.2 mM or less, or 1.1 mM or less.
- Shikimic acid may be included in a concentration of 0.8mM to 1.2mM based on the total volume of the composition. Most preferably, the shikimic acid may be included at a concentration of 1 mM based on the total volume of the composition.
- the plant extract or plant stem cell extract may comprise from 0.0001% (w / v) to 45% (w / v) of the sikimic acid based on the total volume of the extract.
- shikimic acid When included in this range of shikimic acid may have an excellent Oct3 / 4 gene expression effect, ALP expression effect, fibroblast proliferation effect.
- the plant extract or plant stem cell extract herein is based on the total volume of the extract Shikimic acid, 0.001% (w / v) or more, 0.01% (w / v) or more, 0.1% ( w / v) or more, 1% (w / v) or more, 5% (w / v) or more, 10% (w / v) or more, 15% (w / v) or more, 20% (w / v) or more , 25% (w / v) or more, or 30% (w / v) or more, 45% (w / v) or less, 40% (w / v) or less, 38% (w / v) Up to 36% (w / v), up to 34% (w / v), up to 33% (w / v), or up to 32% (w / v).
- the plant extract or plant stem cell extract herein may comprise from 32% (w / v) to 34% (w / v) of the shikimic acid based on the total volume of the extract, more preferably Preferably 32.75% (w / v).
- the composition is a plant extract or plant stem cell extract based on the total volume of the composition in consideration of the concentration of the shikimic acid and the extract of the concentration of shikimic acid contained in the extracts described above And may be at a concentration of contained shikimic acid based on the total volume of the composition.
- the plant extract or plant stem cell extract included in the composition based on the total volume of the composition is at least 0.001 ug / ml, at least 0.01 ug / ml, at least 0.1 ug / ml, at least 1 ug / ml, at least 10 ug / ml , Over 50ug / ml, over 100ug / ml, over 0.3mg / ml, over 0.4mg / ml, over 0.5mg / ml, over 0.6mg / ml, over 0.7mg / ml, over 1mg / ml, over 1.5mg / ml Or more, 2 mg / ml, 5 mg / ml or more, 10 mg / ml or more, 20 mg / ml or more, or 50 mg / ml or more and 1 g / ml or less, or 10 g / ml,
- Measurement of shikimic acid included in the plant extract or plant stem cell extract herein is 250 * 4.60 mm, 5 micron as a Gemini 5u C18 110 A (5 ⁇ m, 4.6 X 250nm, Phenomenex) column using Waters 1525 ⁇ Binary HPLC Pump It may have a standard of, and may be measured by using the mobile solvent A as water (containing 0.1% TFA) and the solvent B as acetonitrile (containing 0.1% TFA).
- “Sequoia” herein includes redwood ( Sequoia sempervirens ), Big Tree ( Sequoiadendron giganteum ) or Metasequoia glyptostroboides .
- Redwood also known as the American Cedar, is a pine tree, the cypress family, and grows only on the northwest coast of California, the southwest of Oregon, and New Zealand. It is 2500 to 3000 years old and the largest tree in the world with a maximum height of 112m. 2.5 to 4.5 m in diameter, 50 to 100 m in height, and bark 20 to 30 cm thick. Leaves are similar to yeast, 1-3cm in length, with sharp tips and distinct veins. The leaf surface is dark green and the back side is white.
- the Big Tree ( Sequoiadendron giganteum ) is the only species in the Sequoia dendron, growing at 1500 to 2500 meters above sea level in the western Sierra Nevada Mountains of California, USA, 3.5 to 6 meters in diameter, 60 to 90 meters in height, and around 10 meters in diameter. .
- the leaves are similar to cedar and 1cm long, arranged in a spiral shape, but the leaves on the mature branches look like scales.
- Metasequoia glyptostroboides is a tree of the cypressaceae family and is the only surviving species in the genus Metasequoia. In the country of origin, it grows up to 35m of toil and the bark is grayish brown and stripped vertically. The branches spread to the side, and the leaves are opposite each other in a line, and are 10 ⁇ 23mm long and 1.5 ⁇ 2mm wide. It has a sharp tip and leaves of brown and red color. Flowers bloom in February-March, male and female, and male flowers are gunshot inflorescences hanging from the ends of axillary branches. There are 20 stamens. Female flowers hang on the ends of branches and bloom in March. Fruits are coniferous, 18 ⁇ 25mm long, round, ripe and brown, with oval seeds with wings. It is a deciduous coniferous tree and its origin is Sichuan, Hubei, China, and is distributed in Korea and China.
- Callus is an undifferentiated irregular cell mass, which is typical of tumor tissue formed by the meristem that forms around the wound when the plant is injured. Plants are composed of meristems that divide into cells and permanent tissues that do not. Cells are first formed by culturing cells in nutrient media and growing. Thereafter, an embryonic embryo is formed and differentiated into plants. Callus is also called 'plant stem cells'.
- extract includes all materials obtained by extracting the components of natural products, regardless of the extraction method, extraction solvent, extracted components or the form of the extract, and extracts the substances obtained by extracting the components of natural products. It is a broad concept that includes all of the materials that can be obtained by processing or processing in a method.
- Sequoia as used herein may be included in the form of an extract, or may be included as a ground powder of the herbal medicine, or dry ground powder of the herbal medicine, but is not limited thereto.
- the sequoia used in the present specification is not limited to the method of obtaining, and may be grown and used or purchased and commercially available, and may mean all of them including the ground and the underground of the sequoia.
- the ground portion may include sequoia fruit, leaves and stems, and the underground portion may include roots, but is not limited thereto.
- plant extract includes all substances obtained by extracting a plant component, such as sequoia, regardless of the extraction method, the extraction solvent, the extracted component or the form of the extract, and the heat in the process of extracting the component. , Including a material obtained by an extraction method including a process of treating with an acid, a base, an enzyme, and the like, and extracting a plant component such as a sequoia It is a broad concept that includes all of the materials that can be obtained by treatment.
- plant stem cell extract includes all substances obtained by culturing stem cells of plants such as sequoias and extracting the active ingredient, regardless of the extraction method, extraction solvent, extracted component or extract form. It is an active ingredient of a stem cell of a plant such as sequoia, which includes a substance obtained through an extraction method including a process of treating with heat, acid, base, enzyme, etc. in extracting the component. It is a broad concept that includes all materials that can be obtained by extracting the material obtained by extracting and then processing or processing by other methods.
- the method of the present invention includes culturing plant stem cells or all kinds of induced pluripotent plant stem cells derived by various methods and preparing extracts therefrom, which can be carried out according to general methods known in the art. .
- culturing plant stem cells or all kinds of induced pluripotent plant stem cells induced by various methods and treating them with proteolytic enzymes collecting suspended solids or reacting and filtering plant stem cells at 65 ° C. for 2 hours.
- the protein or shikimic acid derived from each cell can be extracted.
- callus powder may be used.
- Sequoia callus extract in the present specification is i) inducing callus (callus) from Sequoia; ii) solid cell culture of the callus to establish a stem cell line; iii) producing a large amount of the active ingredient through suspension cell culture; And it can be obtained through the step of extracting the produced active ingredient.
- a method of extracting an active ingredient from Sequoia callus may be extracted by a plant culture method of a cell line derived from a tissue explant of the plant, such as an extraction method known from Korean Patent Publication No. 2007-0113193. It can be extracted by adding a mixture of alcohols of 5-carbon atoms or less to a stable plant cell line derived from Sequoia, but is not limited to the above extraction method.
- sequoia callus extract or sequoia callus powder may be used commercially available herein.
- the sequoia callus extract may be prepared by dissolving sequoia callus powder in a solvent, wherein the solvent includes at least one selected from the group consisting of water, an organic solvent, and a mixture of water and an organic solvent.
- the water may include distilled water or purified water
- the organic solvent may be selected from the group consisting of alcohols, acetone, ether, ethyl acetate, diethyl ether, ethyl methyl ketone, and chloroform, including C 1 to C 5 lower alcohols.
- BG butylene glycol
- EtOH ethanol
- DMSO dimethyl sulfoxide
- the concentration of the shikimic acid or protein extract derived from the plant is preferably 10 ug / ml to 1 mg / ml based on the total volume of the composition including the extract, more preferably about 500 ug / ml. If the concentration of the protein extract is out of the above range because the induction efficiency of the customized pluripotent stem cells or the cells treated with the extract may be killed.
- the method of the present invention comprises the step of injecting the protein extract isolated from plant stem cells or all kinds of induced pluripotent plant stem cells induced by various methods into adult derived cells.
- the adult-derived cells may include human dermal fibroblasts or neonatal human dermal fibroblasts.
- cell membrane permeation promoting compounds e.g., streptolysin O or digitonin
- permeabilization reversible small holes
- the method for producing pluripotent stem cells comprising
- the cell pellet is resuspended in embryonic stem cell culture medium and seeded in a dish;
- the present invention includes the steps of culturing cells injected with shikimic acid, extracts or compositions, to produce cells with pluripotency, such as embryonic stem cells.
- the adult-derived cells injected with them are cultured using a general cell culture medium, and then transferred to a culture condition with a feeder cell layer to perform further culture. Can be.
- DMEM normal cell cultures
- FBS normal cell cultures
- 10-100U / ml penicillin, 20-80mg / ml streptomycin are used until colonies are formed after the injection of the above-mentioned sikimic acid, extract or composition.
- the colonies were formed, and then transferred to the culture conditions with the feeder cell layer and subcultured every 5-8 days in the embryonic stem cell culture medium, and the medium was exchanged daily.
- Supporting cells of the present invention may include, but are not limited to, STO cells.
- Pluripotent stem cells induced by the extract were 15-25% KSR (Knockout serum replacement), 1-4 mM L-glutamine, 0.05-0.2 mM non-essential amino acids, 0.05-0.2 in DMEM (Dulbecco's Modified Eagle Medium) / F12 Cultures can be incubated with addition of mM ⁇ -mercaptoethanol, 30-70 U / ml penicillin, 30-70 mg / ml streptomycin, and 1-30 ug / ml bFGF. It will be readily appreciated by those skilled in the art that the concentration of the compound added to the DMEM may vary within a range capable of achieving the effects of the present invention.
- the present invention comprises the steps of a) extracting the protein from the plant stem cells or all kinds of induced pluripotent plant stem cells induced by various methods;
- the method of the present invention is indistinguishable from embryonic stem cells from adult-derived cells using shikimic acid, plant extracts, plant stem cells or all kinds of induced pluripotent plant stem cell extracts derived from various methods or compositions containing them. It is characterized by the ability to make cells with such pluripotency.
- the inventors confirmed that pluripotent stem cells are induced through the method of the present invention.
- the pluripotent stem cells induced by the present invention in the shape of the cells are almost identical to the embryonic stem cells (see FIG. 4).
- the characteristic gene Nanog, Oct4
- one aspect of the present invention provides a pluripotent stem cell induced by the method which is an aspect of the present invention.
- the present inventors have confirmed that the self-renewal, which is a characteristic of stem cells, by successive passages of 8-12 times through the above method (see FIG. 6).
- one aspect of the present invention provides a composition comprising pluripotent stem cells prepared according to the method of an aspect of the present invention.
- One aspect of the present invention relates to a composition comprising one or more of shikimic acid, a plant extract comprising shikimic acid, and a plant stem cell extract comprising shikimic acid as an active ingredient.
- the composition may be a pharmaceutical composition, a food composition or a cosmetic composition.
- the composition may be a composition for stem cell activation, skin regeneration or anti-aging.
- a method of administering a composition comprising shikimic acid, a plant extract containing shikimic acid, a plant stem cell extract containing shikimic acid, or a composition comprising one or more thereof to an individual in need of stem cell activation It may be related to a stem cell activation method comprising.
- the administration may be in accordance with the method or dosage of administration described herein.
- the present invention comprises administering to a subject in need of skin regeneration, shikimic acid, a plant extract containing shikimic acid, a plant stem cell extract containing shikimic acid, or a composition comprising one or more thereof. It may be related to the skin regeneration method.
- the present invention comprises administering to a subject in need of anti-aging, shikimic acid, a plant extract containing shikimic acid, a plant stem cell extract comprising shikimic acid, or a composition comprising one or more thereof. It may be related to an anti-aging method.
- the present invention provides a stem cell activation use, skin regeneration use, or anti-aging of shikimic acid, a plant extract containing shikimic acid, a plant stem cell extract containing shikimic acid, or a composition comprising at least one of them. It may be related to the use.
- the present invention includes a stem extract, a plant extract comprising a shikimic acid, a plant stem cell extract containing a shikimic acid, or one or more thereof for use in stem cell activation, skin regeneration, or anti-aging. It may be related to the composition.
- the composition may be a cell therapeutic agent.
- the cell therapeutic agent may be used for the formation of hepatocytes, adipocytes, bone cells, chondrocytes, muscle cells, neurons, cardiomyocytes, vascular endothelial cells and the like.
- the present invention comprises administering shikimic acid, a plant extract comprising shikimic acid, a plant stem cell extract comprising shikimic acid, or a composition comprising one or more thereof to an individual in need of cell therapy. It may be related to a method of cell treatment.
- the present invention may be directed to a cell therapeutic use of shikimic acid, a plant extract comprising shikimic acid, a plant stem cell extract comprising shikimic acid, or a composition comprising one or more thereof.
- the present invention may be directed to shikimic acid, a plant extract comprising shikimic acid, a plant stem cell extract comprising shikimic acid, or a composition comprising one or more thereof for use in cell therapy.
- the term 'cell therapeutic agent' refers to a medicinal product (US FDA regulation) used for the purpose of treatment, diagnosis, and prevention of cells and tissues prepared by isolation, culture, and special manipulation from humans.
- a drug used for the purpose of treatment, diagnosis, and prevention through a series of actions, such as proliferating, selecting, or otherwise altering the biological properties of a living autologous, allogeneic, or heterologous cell in order to restore it.
- Cell therapy agents are largely classified into somatic cell therapy and stem cell therapy according to the degree of differentiation of cells, and the present invention relates in particular to stem cell therapy.
- One aspect of the present invention provides a food composition comprising shikimic acid, a plant extract containing shikimic acid, a plant stem cell extract or pluripotent stem cells according to the present specification.
- the composition may contain other components and the like that can give a synergistic effect to the main effect within a range that does not impair the main effect of the present invention.
- additives such as perfumes, pigments, fungicides, antioxidants, preservatives, humectants, thickeners, inorganic salts, emulsifiers and synthetic polymer materials may be further included to improve physical properties.
- the food composition includes, but is not limited to, health food compositions, functional food compositions, supplements, processed food compositions, food additives and the like.
- One aspect of the present invention provides a cosmetic composition
- a cosmetic composition comprising shikimic acid, a plant extract containing shikimic acid, a plant stem cell extract or pluripotent stem cells according to the present specification.
- the cosmetic composition contains a cosmetically or dermatologically acceptable medium or base.
- compositions obtained by dispersing the oil phase in solutions, gels, solids, pasty anhydrous products, aqueous phases, emulsions obtained by dispersing the aqueous phase in oil phases, multi emulsions, suspensions, micro emulsions, micro Capsules, microgranulocytes, ionic (liposomal) and nonionic vesicle dispersants, foams, aerosols or patches containing further compressed propellant may be used.
- These compositions can be prepared according to conventional methods in the art.
- the cosmetic composition may contain other ingredients in addition to the above substances in a range that does not impair the main effect, and preferably may have a synergistic effect on the main effect, and other cosmetics in addition to the active ingredient of the present invention Depending on the formulation of the composition or the purpose of use, those skilled in the art can appropriately select and blend without difficulty.
- the cosmetic composition of the present invention may include other ingredients which are usually formulated into the cosmetic composition as necessary in addition to the active ingredient, and examples thereof include oil-fat ingredients, humectants, emollients, surfactants, organic and inorganic pigments, organic Powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, stabilizers, thickeners, glycerin, pH regulators, alcohols, pigments, flavorings, blood circulation accelerators, cooling agents, limiting agents, purified water and the like.
- Other compounding components that may be included in the cosmetic composition is not limited thereto, and the compounding amount of the above components is possible within a range that does not impair the object and effect of the present invention.
- the formulation of the cosmetic composition is not particularly limited and may be appropriately selected as desired.
- supple lotion, nourishing lotion, essence, nourishing cream, massage cream, pack, gel, makeup base, foundation, powder, lipstick, patch, spray, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water One selected from the group consisting of cleanser, hair shampoo, hair conditioning, hair treatment, hair essence, hair lotion, scalp hair tonic, scalp essence, hair gel, hair spray, hair pack, body lotion, body cream, body oil and body essence It may be prepared in the above formulation, but is not limited thereto.
- One aspect of the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising shikimic acid, a plant extract containing shikimic acid, a plant stem cell extract or pluripotent stem cells according to the present specification.
- Such pharmaceutical compositions may contain, in addition to the active ingredient, preservatives, stabilizers, hydrates, emulsifiers, salts and / or buffers for osmotic pressure control, diluents (e.g.
- lactose dextrose, sucrose, mannitol, sorbitol, cellulose or glycine
- Glidants such as silica, talc, stearic acid and magnesium or calcium salts or polyethylene glycols thereof or binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose or polyvinylpi
- binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose or polyvinylpi
- Pharmaceutical adjuvant or other therapeutically useful substances such as rolidine).
- other pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, or sweeteners such as starch, agar, alginic acid or sodium salts thereof may be included.
- compositions can be formulated in various oral or parenteral dosage forms according to conventional methods.
- the oral dosage forms include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, powders, powders, fine granules, granules, pellets, and the like, and these formulations include surfactants in addition to the active ingredients.
- Diluents such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine
- glidants such as silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols.
- Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners.
- binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt
- Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners.
- the tablets can be prepared by conventional mixing, granulating or coating methods.
- parenteral administration agent may be, for example, formulations such as injections, drops, ointments, lotions, gels, creams, sprays, suspensions, emulsions, suppositories, and patches, but are not limited thereto. no.
- the pharmaceutical composition according to an aspect of the present invention may be administered parenterally, rectally, topically, transdermally, subcutaneously, and the like.
- the composition is based on the formulation and criteria suitable for each administration. In particular, in the case of intravenous injection, all additives not suitable for this are excluded, and the purity of the composition itself is also very high.
- the applied amount of the active ingredient will vary depending on the age, sex, weight, disease, pathological condition, route of administration and prescriber's judgment of the subject to be treated. Application amount determination based on these factors is within the level of skill in the art. Typical dosages are preferably 30 ug / ml to 1 mg / ml, but are not limited thereto.
- pluripotent stem cells prepared by the method according to the present invention it is preferable to be used in the formulation of the injection in the pharmaceutical composition.
- Pluripotent stem cells prepared by the method according to the present invention are injected into the skin similarly to botox that is commonly used for the purpose of removing wrinkles by injection into the skin to activate skin stem cells, and to promote the proliferation of skin cells, etc. Through the effects of skin regeneration, anti-aging, improve elasticity, it can exhibit such effects as wrinkles.
- One aspect of the present invention also provides a composition including, but not limited to, shikimic acid, a plant extract comprising shikimic acid, a plant stem cell extract, or an experimental reagent or medium composition comprising pluripotent stem cells.
- callus powder as a plant-derived stem cell extract.
- Callus powder that can be used in the present invention is not limited and may be purchased commercially.
- Sequoia callus extract induces callus from the leaves of Sequoia and solid cultures to establish stem cell lines and suspension cell culture to produce active ingredients in large quantities. After production it is extracted and obtained. Extracting the active ingredient from the sequoia callus can be extracted by the plant culture method of cell lines derived from the tissue explant of the plant, such as the extraction method known in Korea Patent Publication No. 2007-0113193, although it can be eluted by adding a mixture of alcohols of 5-carbon atoms or less to a stable plant cell line derived from Sequoia, it is not limited to the above extraction method.
- sequoia callus power (commercially available from BiofdNC) was used. Specifically, human dermal fibroblasts (human dermal fibroblasts) were made into individual cells using trypsin-EDTA, followed by washing with cold PBS (phosphate buffered saline). The cell pellet was resuspended to 100 ⁇ l / 100,000 cells of cold Ca2- and Mg2-free Han's balanced salt solution (HBSS) and transferred to a 1.5 ml tube.
- HBSS Han's balanced salt solution
- digitonin (20ug / ml) and transport solution 110 mM potassium acetate, 5 mM sodium acetate, 2 mM magnesium acetate, 1 mM EGTA instead of SLO
- 200ul of 2 mM DTT, proteaseinhibitor cocktail, 20 mM HEPES pH7.3 200ul of 2 mM DTT, proteaseinhibitor cocktail, 20 mM HEPES pH7.3
- the sample was reacted for 50 minutes in a 37 °C water bath, mixed up and down once every 10 minutes.
- the reaction sample is placed on ice and 200 ⁇ l of cold HBSS is added, followed by centrifugation at 120 g for 5 minutes at a swing-out rotor at 4 ° C.
- the cell pellet was resuspended with 200 ⁇ l of plant stem cell extract to 1 ⁇ l / 1000 cells.
- Callus powder was used as a plant stem cell extract (500 ug / ml).
- ATP-regeneration system (10 mM creatine phosphate, and 25 g / ml creatine kinase), 1 mM nucleotide triphosphate, respectively, was added and reacted for 1 hour in a 37 ° C. water bath, mixed up and down once every 10 minutes.
- 1 ml of ES cell medium containing 2 mM CaCl 2 was added to reseal the plasma membrane and reacted in a 37 ° C. incubator for 2 hours.
- the cell pellet was resuspended in embryonic stem cell culture medium and seeded in a dish coated with 0.1% gelatin.
- Example 2 A step of producing cells with pluripotency, such as embryonic stem cells, by culturing the cells injected with the extract
- DMEM Dulbecco's Modified Eagle Medium
- FIG 1 is a schematic diagram showing the entire experimental process of inducing pluripotent stem cells according to the method of the present invention.
- 2 to 4 show that pluripotent stem cells were induced at 5, 10 and 32 days of culture, respectively, and FIGS. 5 and 6 show alkaline phosphatase at 32 and 50 days of culture, respectively.
- the pluripotent stem cells induced according to the method of the present invention show alkaline phosphatase staining positive (purple) characteristic of embryonic stem cells.
- RT-PCR reverse transcriptase-polymerase chain reaction
- pluripotent stem cells hiPS
- hES embryonic stem cells
- Sequoia callus extract dissolved in a solvent mixed with BG and EtOH in the sequoia extract obtained according to the method of Example 4 was analyzed by using an HPLC machine.
- LC spectrum of the sequoia extract is as shown in Figure 8 and the results are shown in Table 1 below.
- % Area represents% (w / v) of the substance contained in the sequoia extract.
- Neonatal human dermal fibroblasts (NHDF-Neonatal) (CC-2509, Lonza, USA) were treated with 10 ⁇ M and 10 mM of shikimic acid, respectively. NHDF-Neonatal without any treatment was set as negative control.
- Shikimic acid the main component of Sequoia callus extract
- the shikimic acid or the extract including the same according to the present invention is injected into the somatic cells, the Oct3 / 4 gene can be expressed to induce customized pluripotent stem cells.
- Test Example 3-1 Test for Confirming Increased Expression of Alkaline Phosphatase (ALP), a Stem Cell Activity Marker
- ALP Alkaline Phosphatase
- the HDF treated with Sequoia callus extract has a lot of stained portion compared to normal (HDF), indicating that the expression of ALP is significantly increased.
- the treatment of sequoia callus extract can confirm that the ALP is expressed more than the treatment with shikimic acid.
- ALP is expressed in cells three days after the expression of genes such as Oct4, a marker known to play an important role in the early stage of dedifferentiated stem cell formation ( marker). Therefore, when the sequoia callus extract according to the present invention is injected into the somatic cells, the expression of ALP is significantly increased, and since the Oct4 gene is expressed, the customized pluripotent stem cells can be induced.
- Sequoia callus extract according to the present invention has a remarkable effect of activating stem cells in the light of promoting the expression of the stem cell activity marker ALP.
- Test Example 3-2 Experiment of Confirming Increased Expression of Alkaline Phosphatase (ALP), a Stem Cell Activity Marker
- NHDF- neo four exit (Neonatal) (CC-2509, Lonza, USA) acid 10uM, 10mM Sikkim gae to 1x10 6 were each treated.
- NHDF-Neonatal without any treatment was set as negative control.
- 100,000 cells were attached to 6-well plates, and on day 12, 7 days later, fixed with 3.8% formaldehyde in PBS for 15 minutes at room temperature, followed by diluting 200ul of NBT / BCIP® ALP substrate solution in 10 ml of ALP buffer.
- 0.5ml of the solution was treated 20 hours later and observed 40 times with an Olympus CKX41 optical microscope. The results obtained through observation are shown in FIG. 13.
- ALP is a marker known to play an important role in the early stage of dedifferentiated stem cell formation as it begins to be expressed three days after the gene such as Oct4. . Therefore, when the shikimic acid and the plant extract containing the same according to the present invention are injected into the somatic cells, the expression of ALP is significantly increased, and also the Oct4 gene is expressed, thereby inducing customized pluripotent stem cells.
- the Shikimic acid and the plant extract containing the same according to the present invention shows a remarkable effect of activating stem cells in the light of promoting the expression of the stem cell activity marker ALP.
- NHDF- neo leaving four was filtered with an embodiment (CC-2509, Lonza, USA ) 5x10 5 gae buffer Sami Billy hybridization buffer (Permeablization buffer) and digi tonin (digitonin) process and 0.4um filter to 10ug / ml in The sequoia callus extract according to 4 (BG and EtOH mixed solvent) 100ppm, 200ppm and 20ppm DMSO solution was treated. NHDF-Neonatal without any treatment was set as negative control. On day 10 of the passage, 200 cells were adhered to a 60 mm plate, and on day 23, ice-cold methanol was washed on ice with ice-cold PBS, and stored at -20 ° C.
- sequoia callus extract according to the present invention can be confirmed that significantly promote the proliferation of fibroblasts.
- the sequoia extract according to the present invention has an effect of promoting skin regeneration.
- 200 cells were attached to a 60 mm plate, and on day 17, ice-cold methanol was washed on ice with ice-cold PBS and stored at -20 degrees. The cells were fixed for 10 minutes. 1% crystal violet in Ethanol stock solution was diluted 1/10 in PBS to make an experimental solution. After treatment for 5 to 10 minutes, the cells were dyed and washed 4 times with PBS.
- shikimic acid according to the present invention significantly promotes the proliferation of fibroblasts.
- sekimic acid and sequoia extract containing the same according to the present invention have an effect of promoting skin regeneration.
- sequoia callus extract according to the present invention can be confirmed that significantly promote the division of fibroblasts.
- the sequoia extract according to the present invention in view of significantly promoting fibroblast division of dermal cells, the sequoia extract according to the present invention can be seen that exhibits the effect of promoting skin regeneration.
- Sikkim acid or sequoia callus extract according to Example 4 40ug, vitamin E 9mg, vitamin C 9mg, palm oil 2mg, vegetable hardened oil 8mg, beeswax 4mg and lecithin 9mg are mixed and mixed according to a conventional method to prepare a soft capsule filler Manufacture. 400 mg per capsule is filled to prepare a soft capsule.
- a soft capsule sheet is prepared at a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerine, and 10 parts by weight of sorbitol solution and filled with the filler to prepare a soft capsule containing 400 mg of the composition according to the present invention.
- Sikkim acid or sequoia callus extract according to Example 4 40 ⁇ g, vitamin E 9mg, vitamin C 9mg, galactooligosaccharide 200mg, lactose 60mg and maltose 140mg were mixed and granulated using a fluidized bed dryer and then sugar ester (sugar ester) 6 mg is added. Tablets are prepared by tableting 500 mg of these compositions in a conventional manner.
- Sikkim acid or 40 ug of sequoia callus extract according to Example 4 vitamin E 9mg, vitamin C 9mg, anhydrous glucose of 250mg and starch 550mg were mixed, molded into granules using a fluidized bed granulator, and then packed into a fabric To prepare.
- Injectables were prepared by conventional methods according to the compositions set forth in Table 4 below.
- Table 4 Compounding ingredient content Sikkim acid or sequoia callus extract according to example 4 40 ⁇ g Sterile Distilled Water for Injection Quantity pH regulator Quantity
- Injections are prepared in the above amounts per ampoule (2 ml) according to the conventional method for preparing injections.
- composition shown in Table 5 was prepared in the conventional method for the flexible cosmetic.
- Table 5 Compounding ingredient Content (% by weight) Sikkim acid or sequoia callus extract according to example 4 0.2 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxy Vinyl Polymer 0.1 Fiji-12 nonylphenyl ether 0.2 Polysorbate 80 0.4 ethanol 10.0 Triethanolamine 0.1 Preservative, coloring, flavoring Quantity Purified water Remaining amount
- Nutritional longevity was prepared according to the composition described in Table 6 below in a conventional manner.
- Table 6 Compounding ingredient Content (% by weight) Sikkim acid or sequoia callus extract according to example 4 1.0 glycerin 3.0 Butylene glycol 3.0 Propylene glycol 3.0 Carboxy Vinyl Polymer 0.1 Beeswax 4.0 Polysorbate 60 1.5 Caprylic / Capric Triglycerides 5.0 Squalane 5.0 Sorbitassquioleate 1.5 Liquid paraffin 0.5 Cetearyl Alcohol 1.0 Triethanolamine 0.2 Preservative, coloring, flavoring Quantity Purified water Remaining amount
- Nutritional cream was prepared in a conventional manner according to the composition shown in Table 7.
- Table 8 Compounding ingredient Content (% by weight) Sikkim acid or sequoia callus extract according to example 4 2.0 glycerin 8.0 Butylene glycol 4.0 Liquid paraffin 45.0 Beta Glucan 7.0 Carbomer 0.1 Caprylic / Capric Triglycerides 3.0 Beeswax 4.0 Cetearyl Glucoside 1.5 Sesqui oleic acid sorbitan 0.9 Vaseline 3.0 paraffin 1.5 Preservative, coloring, flavoring Quantity Purified water Remaining amount
- Table 9 Compounding ingredient Content (% by weight) Sikkim acid or sequoia callus extract according to example 4 0.2 glycerin 4.0 Polyvinyl alcohol 15.0 Hyaluronic acid extract 5.0 Beta Glucan 7.0 Allantoin 0.1 Nonyl Phenyl Ether 0.4 Polysorbate 60 1.2 Ethanol preservative 6.0 Preservative, coloring, flavoring Quantity Purified water Remaining amount
- Table 10 Compounding ingredient content Sikkim acid or sequoia callus extract according to example 4 20 ⁇ g Vitamin A Acetate 70 ⁇ g Vitamin E 1.0mg Vitamin B1 0.13mg Vitamin B2 0.15mg Vitamin B6 0.5mg Vitamin B12 0.2 ⁇ g Vitamin c 10mg Biotin 10 ⁇ g Nicotinic acid amide 1.7mg Folic acid 50 ⁇ g Calcium Pantothenate 0.5mg Ferrous sulfate 1.75mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg Potassium phosphate monobasic 15 mg Dicalcium Phosphate 55 mg Potassium citrate 90 mg Calcium carbonate 100mg Magnesium chloride 24.8 mg
- composition ratio of the said vitamin and mineral mixture was mixed and consisted with the component suitable for a healthy food in a preferable Example, the compounding ratio may be arbitrarily modified.
- Table 11 Compounding ingredient content Sikkim acid or sequoia callus extract according to example 4 20 ⁇ g Citric acid 1000 mg oligosaccharide 100 g Taurine 1 g Purified water Remaining amount
- the above ingredients are mixed according to a conventional method for preparing a health beverage, then stirred and heated at 85 ° C. for about 1 hour, and then the resulting solution is filtered and sterilized.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Transplantation (AREA)
- Hematology (AREA)
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016548991A JP6606085B2 (ja) | 2013-10-17 | 2014-10-16 | 増加されたコロニー生成力及び増殖力を有するヒト細胞の製造方法 |
EP17164428.9A EP3275999B1 (fr) | 2013-10-17 | 2014-10-16 | Procédé d'induction de cellules souches pluripotentes et cellules souches pluripotentes préparées selon ledit procédé |
EP14853540.4A EP2977446B1 (fr) | 2013-10-17 | 2014-10-16 | Procédé d'induction de cellules souches pluripotentes et cellules souches pluripotentes préparées au moyen dudit procédé |
US14/779,136 US20160215269A1 (en) | 2013-10-17 | 2014-10-16 | Method for inducing pluripotent stem cells and pluripotent stem cells prepared by said method |
CN201480019489.5A CN105722974B (zh) | 2013-10-17 | 2014-10-16 | 全能干细胞的诱导方法、及用该方法制备的全能干细胞 |
HK16108463.3A HK1220487A1 (zh) | 2013-10-17 | 2016-07-18 | 全能幹細胞的誘導方法、及用該方法製備的全能幹細胞 |
US15/377,464 US10251824B2 (en) | 2013-10-17 | 2016-12-13 | Method for inducing pluripotent stem cells and pluripotent stem cells prepared by said method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130123860A KR102105532B1 (ko) | 2013-10-17 | 2013-10-17 | 만능 줄기세포의 유도 방법 및 상기 방법에 의해 제조된 만능줄기세포 |
KR10-2013-0123860 | 2013-10-17 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/779,136 A-371-Of-International US20160215269A1 (en) | 2013-10-17 | 2014-10-16 | Method for inducing pluripotent stem cells and pluripotent stem cells prepared by said method |
EP17164428.9A Previously-Filed-Application EP3275999B1 (fr) | 2013-10-17 | 2014-10-16 | Procédé d'induction de cellules souches pluripotentes et cellules souches pluripotentes préparées selon ledit procédé |
US15/377,464 Division US10251824B2 (en) | 2013-10-17 | 2016-12-13 | Method for inducing pluripotent stem cells and pluripotent stem cells prepared by said method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015056982A1 true WO2015056982A1 (fr) | 2015-04-23 |
Family
ID=52828359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/009702 WO2015056982A1 (fr) | 2013-10-17 | 2014-10-16 | Procédé d'induction de cellules souches pluripotentes et cellules souches pluripotentes préparées au moyen dudit procédé |
Country Status (7)
Country | Link |
---|---|
US (2) | US20160215269A1 (fr) |
EP (2) | EP2977446B1 (fr) |
JP (1) | JP6606085B2 (fr) |
KR (1) | KR102105532B1 (fr) |
CN (1) | CN105722974B (fr) |
HK (1) | HK1220487A1 (fr) |
WO (1) | WO2015056982A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113005079A (zh) * | 2021-05-08 | 2021-06-22 | 河北驰熙科技发展有限公司 | 一种人骨髓间充质干细胞体外扩增用添加剂及扩增方法 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102016062B1 (ko) * | 2016-04-26 | 2019-08-30 | 주식회사 바이오에프디엔씨 | 미백개선과 주름개선 효과를 갖는 배 캘러스와 유자 캘러스 소재 |
KR101920650B1 (ko) * | 2018-01-24 | 2019-01-30 | 주식회사 바람인터내셔날 | 다알리아 조성물, 다알리아 조성물 분말, 화장료 조성물 및 그 제조방법 |
KR102352636B1 (ko) * | 2018-12-28 | 2022-01-19 | (주)앗코스텍 | 팔각회향 추출물 또는 시킴산을 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물 |
EP3808411A1 (fr) * | 2019-10-16 | 2021-04-21 | Mesoestetic Pharma Group, S.L. | Compositions cosmétiques et utilisation de celles-ci |
KR102299417B1 (ko) * | 2019-12-12 | 2021-09-07 | (주)아모레퍼시픽 | 노화 피부세포 주변 환경변화 유도 촉진용 조성물 |
KR102408566B1 (ko) * | 2020-04-09 | 2022-06-16 | 대한민국 | 터미날리아 비아라타 추출물을 이용한 피부 주름 개선용 조성물 |
JPWO2023042826A1 (fr) * | 2021-09-14 | 2023-03-23 | ||
CN114591894B (zh) * | 2022-02-28 | 2024-01-09 | 中国人民解放军总医院 | 一种皮肤多能前体干细胞的制备方法及其应用 |
CN115369081B (zh) * | 2022-08-24 | 2024-01-02 | 吉林大学 | 一种干细胞生长促进剂及其制备的细胞培养基和应用 |
WO2024128333A1 (fr) * | 2022-12-12 | 2024-06-20 | 주식회사 뉴셀팜 | Composition utilisant un extrait veratrum versicolor pour atténuer les rides de la peau et blanchir la peau |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19980034293U (ko) * | 1996-12-10 | 1998-09-15 | 박병재 | 자동차의 배기 가스 후압력 감소 장치 |
KR20070113193A (ko) | 2005-03-24 | 2007-11-28 | 지울리아니 에스.피.에이. | 탈모를 예방하고, 모발의 성장을 촉진하고, 피지의 생성을조절하기 위한 아주가 렙탄스(Ajugareptans)의 식물성 추출물에 기초한 조성물 |
US20080095866A1 (en) * | 2004-09-14 | 2008-04-24 | Ajinomoto Omnichem S.A. | Topical Compositions Containing Phosphorylated Polyphenols |
KR20110032989A (ko) * | 2009-09-22 | 2011-03-30 | 서울대학교병원 | 성체세포로부터 만능줄기세포를 유도하는 방법 및 그 방법에 의해 제조된 만능줄기세포 |
KR101121883B1 (ko) * | 2010-11-24 | 2012-03-20 | 주식회사 바이오에프디엔씨 | 세인트존스워트 캘러스 추출물을 함유하는 피부 외용제 조성물 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19818541C2 (de) * | 1998-04-24 | 2003-04-10 | Forschungszentrum Juelich Gmbh | Mikrobielle Herstellung von Substanzen aus dem aromatischen Stoffwechsel / III |
US6613552B1 (en) * | 1999-01-29 | 2003-09-02 | Board Of Trustees Operating Michigan State University | Biocatalytic synthesis of shikimic acid |
TWI282275B (en) * | 2000-08-17 | 2007-06-11 | Control Ox Oy | Plant-derived and synthetic phenolic compounds and plant extracts, effective in the treatment and prevention of chlamydial infections |
US20020142397A1 (en) * | 2000-12-22 | 2002-10-03 | Philippe Collas | Methods for altering cell fate |
US7132286B2 (en) * | 2001-06-18 | 2006-11-07 | Psychiatric Genomics, Inc. | Method for neural stem cell differentiation using valproate |
JP5559463B2 (ja) * | 2008-03-12 | 2014-07-23 | 株式会社コーセー | シキミ酸を有効成分とする美白剤 |
KR101526303B1 (ko) * | 2008-03-31 | 2015-06-05 | (주)아모레퍼시픽 | 항노화용 화장료 조성물 |
KR101757734B1 (ko) * | 2010-11-30 | 2017-07-17 | (주)아모레퍼시픽 | 세콰이어 캘러스 추출물을 함유하는 지방유래 줄기세포의 줄기세포성 증진용 및 피부세포 증식용 조성물 |
JP5826921B2 (ja) * | 2011-05-16 | 2015-12-02 | ビーチ ツリー ラボ、インコーポレイテッド | 隔離されたバクテリアに関連する疾患の治療方法 |
KR101279092B1 (ko) * | 2011-09-28 | 2013-06-26 | 건국대학교 산학협력단 | 형절전환체를 이용한 클로로겐산의 합성 |
-
2013
- 2013-10-17 KR KR1020130123860A patent/KR102105532B1/ko active IP Right Grant
-
2014
- 2014-10-16 WO PCT/KR2014/009702 patent/WO2015056982A1/fr active Application Filing
- 2014-10-16 JP JP2016548991A patent/JP6606085B2/ja active Active
- 2014-10-16 CN CN201480019489.5A patent/CN105722974B/zh active Active
- 2014-10-16 EP EP14853540.4A patent/EP2977446B1/fr active Active
- 2014-10-16 EP EP17164428.9A patent/EP3275999B1/fr active Active
- 2014-10-16 US US14/779,136 patent/US20160215269A1/en not_active Abandoned
-
2016
- 2016-07-18 HK HK16108463.3A patent/HK1220487A1/zh unknown
- 2016-12-13 US US15/377,464 patent/US10251824B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19980034293U (ko) * | 1996-12-10 | 1998-09-15 | 박병재 | 자동차의 배기 가스 후압력 감소 장치 |
US20080095866A1 (en) * | 2004-09-14 | 2008-04-24 | Ajinomoto Omnichem S.A. | Topical Compositions Containing Phosphorylated Polyphenols |
KR20070113193A (ko) | 2005-03-24 | 2007-11-28 | 지울리아니 에스.피.에이. | 탈모를 예방하고, 모발의 성장을 촉진하고, 피지의 생성을조절하기 위한 아주가 렙탄스(Ajugareptans)의 식물성 추출물에 기초한 조성물 |
KR20110032989A (ko) * | 2009-09-22 | 2011-03-30 | 서울대학교병원 | 성체세포로부터 만능줄기세포를 유도하는 방법 및 그 방법에 의해 제조된 만능줄기세포 |
KR101121883B1 (ko) * | 2010-11-24 | 2012-03-20 | 주식회사 바이오에프디엔씨 | 세인트존스워트 캘러스 추출물을 함유하는 피부 외용제 조성물 |
Non-Patent Citations (4)
Title |
---|
DENIS V. BOCHKOV: "Shikimic acid: review of its analytical, isolation, and purification techniques from plant and microbial sources", J CHEM. BIOL., vol. 5, 2012, pages 5 - 17, XP002759175, DOI: doi:10.1007/s12154-011-0064-8 |
See also references of EP2977446A4 * |
TAKAHASHI K; YAMANAKA S: "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors", CELL, vol. 126, 2006, pages 663 - 676 |
XU, Y. N. ET AL.: "ES cell extract-induced expression of pluripotent factors in somatic cells", THE ANATOMICAL RECORD, vol. 292, no. 8, August 2009 (2009-08-01), pages 1229 - 1234, XP055110618 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113005079A (zh) * | 2021-05-08 | 2021-06-22 | 河北驰熙科技发展有限公司 | 一种人骨髓间充质干细胞体外扩增用添加剂及扩增方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2977446A4 (fr) | 2016-10-26 |
US10251824B2 (en) | 2019-04-09 |
EP2977446B1 (fr) | 2020-12-02 |
CN105722974B (zh) | 2020-03-03 |
EP3275999A1 (fr) | 2018-01-31 |
EP2977446A1 (fr) | 2016-01-27 |
JP2017500882A (ja) | 2017-01-12 |
CN105722974A (zh) | 2016-06-29 |
KR20150044607A (ko) | 2015-04-27 |
KR102105532B1 (ko) | 2020-04-29 |
US20160215269A1 (en) | 2016-07-28 |
HK1220487A1 (zh) | 2017-05-05 |
EP3275999B1 (fr) | 2020-12-02 |
US20170128336A1 (en) | 2017-05-11 |
JP6606085B2 (ja) | 2019-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015056982A1 (fr) | Procédé d'induction de cellules souches pluripotentes et cellules souches pluripotentes préparées au moyen dudit procédé | |
WO2009151302A2 (fr) | Composition anti-âge ou anti-oxydation contenant des lignées de cellules souches végétales dérivées du cambium de panax ginseng comprenant du ginseng sauvage et du ginseng comme principes actifs | |
WO2021261632A1 (fr) | Nouvelle souche de faecalibacterium prausnitzii eb-fpdk11 et utilisation associée | |
WO2013176471A1 (fr) | Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par stat-3, contenant un extrait ou une fraction de salvia plebeia r. br. en tant que principe actif | |
WO2019209068A1 (fr) | Lignée cellulaire sécrétant et exprimant continuellement des protéines hla-g, et procédé pour la produire | |
WO2018056706A1 (fr) | Composition comprenant un peptide dérivé d'une protéine interagissant avec la thiorédoxine ou un polynucléotide codant pour celle-ci en tant que principe actif pour le vieillissement inverse d'une cellule souche âgée et son utilisation | |
WO2016032249A1 (fr) | Composition pharmaceutique contenant un extrait de vaccinium bracteatum thunb. ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une inflammation des nerfs ou des maladies neurodégénératives | |
KR101908221B1 (ko) | 금방동사니 추출물을 포함하는 항비만 조성물 | |
WO2017061769A1 (fr) | Composition de prévention de l'alopécie ou de stimulation de la croissance capillaire contenant un polysaccharide extracellulaire produit par ceriporia lacerata en tant qu'ingrédient actif | |
WO2021080297A1 (fr) | Composition contenant un extrait de fleur d'onagre en tant que principe actif pour prévenir ou traiter l'obésité ou des syndromes métaboliques ainsi induits | |
WO2020251253A1 (fr) | Melon vital pour la prévention ou le traitement de l'obésité et extrait de celui-ci | |
WO2014189176A1 (fr) | Extrait d'ecklonia cava permettant la perte de poids et son procédé de préparation | |
WO2017188690A1 (fr) | Composition permettant d'inhiber la croissance des cellules souches cancéreuses mammaires, comprenant du phénylacétaldéhyde | |
WO2023106777A1 (fr) | Melon vital (kctc14699bp) et composition anti-obésité comprenant un extrait de celui-ci | |
WO2020138834A1 (fr) | Composition pour la prévention ou le traitement de maladies de la peau comprenant de la spirée couronne de mariée | |
KR20140033957A (ko) | 녹차 캘러스 추출물을 함유하는 항염증 화장료 조성물 및 이의 제조방법 | |
WO2021261631A1 (fr) | Nouvelle souche de picalibacterium prosnich eb-fpdk9 et utilisations associées | |
WO2022086218A1 (fr) | Procédé de construction d'un modèle de dermatite atopique à l'aide d'un organoïde cutané dérivé de cellules souches pluripotentes | |
WO2013024960A1 (fr) | Composition médicale contenant un extrait de stauntonia hexaphylla | |
WO2020149538A1 (fr) | Composition pharmaceutique comprenant des cellules souches clonales pour la prévention ou le traitement de la dermatite atopique | |
WO2020040621A1 (fr) | Composition visant à favoriser la différenciation ou la prolifération de cellules souches adipeuses humaines | |
WO2014014177A1 (fr) | Composition, comprenant un extrait de dendropanax morbifera ou un composé dérivé de celui-ci comme principe actif, destinée à la prévention et au traitement de l'hyperplasie prostatique bénigne | |
WO2018155933A1 (fr) | 6,7-diméthoxy-2,2-diméthyl-2h-chromène pour accroître l'expression de l'aquaporine-3 et son utilisation | |
KR20180078433A (ko) | 쑥부쟁이 추출물을 유효성분으로 포함하는 항비만 조성물 | |
WO2023282367A1 (fr) | Composition cosmétique comprenant un extrait de cynanchum atratum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14853540 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14779136 Country of ref document: US Ref document number: 2014853540 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016548991 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |